Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, Inc. for $4.10 per share, a 65% premium to last traded price, post-FDA approval of Unloxcyt for metastatic cutaneous ...
Checkpoint Therapeutics, Inc. announced that the U.S. FDA approved its drug UNLOXCYT™ (cosibelimab-ipdl) in December 2024, making it the first and only anti-PD-L1 treatment for adults with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback